Last reviewed · How we verify
Placebo of aprepitant
Placebo of aprepitant is a Small molecule drug developed by Sun Yat-sen University. It is currently in Phase 3 development for Control arm in aprepitant phase 3 clinical trial (likely chemotherapy-induced nausea and vomiting prevention). Also known as: Comparative arm: Placebo of aprepitant administration.
This is a placebo control arm in a clinical trial and contains no active pharmaceutical ingredient.
This is a placebo control arm in a clinical trial and contains no active pharmaceutical ingredient. Used for Control arm in aprepitant phase 3 clinical trial (likely chemotherapy-induced nausea and vomiting prevention).
At a glance
| Generic name | Placebo of aprepitant |
|---|---|
| Also known as | Comparative arm: Placebo of aprepitant administration |
| Sponsor | Sun Yat-sen University |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
As a placebo, this formulation is designed to be inert and pharmacologically inactive, serving as a control comparator in the phase 3 trial of aprepitant. Placebos are used to establish the true efficacy and safety profile of the active drug by accounting for natural disease progression and psychological effects.
Approved indications
- Control arm in aprepitant phase 3 clinical trial (likely chemotherapy-induced nausea and vomiting prevention)
Common side effects
Key clinical trials
- Pilot Study of Aprepitant Effect on Aldosterone Secretion in Diabetic Patient (Diabetes Mellitus) With Hypertension Associated With Low Renin (PHASE2)
- Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3 (PHASE4)
- Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients (PHASE3)
- Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1) (PHASE2)
- Effect of Aprepitant on Post-operative Nausea and Vomiting in Otologic Surgery (PHASE4)
- Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients (PHASE3)
- Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms (PHASE3)
- EFFECT OF A SUBSTANCE P ANTAGONIST ON THE SECRETION OF ALDOSTERONE IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA SYNDROME AND ARTERIAL HYPERTENSION (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of aprepitant CI brief — competitive landscape report
- Placebo of aprepitant updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI
Frequently asked questions about Placebo of aprepitant
What is Placebo of aprepitant?
How does Placebo of aprepitant work?
What is Placebo of aprepitant used for?
Who makes Placebo of aprepitant?
Is Placebo of aprepitant also known as anything else?
What development phase is Placebo of aprepitant in?
Related
- Manufacturer: Sun Yat-sen University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Control arm in aprepitant phase 3 clinical trial (likely chemotherapy-induced nausea and vomiting prevention)
- Also known as: Comparative arm: Placebo of aprepitant administration
- Compare: Placebo of aprepitant vs similar drugs
- Pricing: Placebo of aprepitant cost, discount & access